May 07, 2021
Article
A recent JAMA study shows a decrease in suicide deaths between 2019-2020, despite a 17% overall increase in mortality.
May 04, 2021
Video
Approximately 30% of schizophrenia patients do not respond to their first treatment.
Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.
Clozapine is considered the gold standard of schizophrenia treatment.
Education could be the best resource in increasing prescription rates for clozapine.
May 03, 2021
Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.
New data show high rate of depressive symptoms in patients with NTFE schizophrenia.
Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.
May 02, 2021
Adults often do not suffer from the symptoms of hyperactivity in ADHD.
New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.
Thyroid Hormone Treatment Intensity May Be Modifiable Risk Factor for CV Mortality
Carolyn Rowley, PhD, Addresses Mental Health and Wellness in People with Sickle Cell Disease
David Au, MD, MS: Lifestyle Interventions for Weight Loss in Obese Patients with COPD
